Tocilizumab is associated with reduction in inflammation and improvement in P/F ratio in critically sick COVID19 patients

Authors:

Muhammad Asim Rana¹, Mubashar Hashmi¹, Muhammad Muneeb Ullah Saif², Muhammad Faisal Munir², Ahad Qayyum³, Rizwan Pervaiz¹, Muhammad Mansoor Hafeez⁴

Affiliations:

- 1. Department of Critical Care, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
- 2. Department of Critical Care Nursing, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
- 3. Department of Nephrology, Division of Medicine, Bahria International Hospital, Lahore, Pakistan.
- 4. Institute of molecular biology and biotechnology, University of Lahore

Abstract:

Introduction: Coronavirus disease 2019 was initially detected in China and has been declared a global pandemic by World Health Organization on March 11, 2020. In the majority of patients, SARS \Box CoV \Box 2 causes a mild to moderate illness characterized by fever and respiratory symptoms, with or without evidence of pneumonia. The recent studies suggest that anti-cytokine targeted therapies might be associated with benefit for patients with severe COVID-19 especially in improving respiratory failure. Tocilizumab, a monoclonal antibody against interleukin 6 (IL6) receptor, is associated with clinical benefit for COVID-19 patients as it inhibits IL6 and decreases inflammation. Methods: As Tocilizumab has been an important part of our treatment and a strict criterion was followed to administer Tocilizumab, a retrospective study design used to assess the beneficial effects of Tocilizumab in improvement of ratio partial pressure of arterial Oxygen and fraction of inspired Oxygen (PaO₂/FiO₂ or P/F ratio) and C- reactive protein (CRP) in COVID19 patients has been done. 60 patients were taken for this study by using convenient sampling technique the data of demographics, laboratory results, and clinical outcomes i.e. improvement of respiratory failure depicted in the form of PF Ratio were obtained from the medical records, Statistical analysis was done with SPSS, version 21.0. Results: Sixty patients (47 males and 13 females) with COVID \Box 19 were included in this study, the mean age of

patients was 53.83 (14 \square 81) years. After administration of Tocilizumab the lab parameters were changed as CRP decreased down to .40 (9.6 \square 73) mg/L but other parameters were not affected. The PF ratio improved in COVID-19 patients after administration of Tocilizumab the median of PF Ratio before treatment was 108 (52 \square 362) and improved up to 128 (37 \square 406) after Tocilizumab therapy. **Conclusion:** In summary, Tocilizumab appears to be associated with improvement in P/F Ratio and CRP in COVID19 patients but other markers did not improve in response to Tocilizumab therapy in severely ill COVID-19 patients.

Keywords: SARS-CoV-2, COVID19, inflammatory markers, P/F ratio, PaO₂/FiO₂, Tocilizumab, CRP, serum Ferritin, Interleukin 6, IL6

Introduction

Coronavirus disease 2019 (COVID19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), was initially detected in China and was later declared a global pandemic by World Health Organization on March 11, 2020 (1).

The clinical spectrum of this illness ranges from asymptomatic infection to acute respiratory distress syndrome (ARDS) (2). In the majority of patients, SARS \Box CoV \Box 2 causes a mild to moderate illness characterized by fever and respiratory symptoms, with or without evidence of pneumonia.(3). However, up to 10% of patients with COVID 19 may develop severe pneumonia with hypoxia, acute respiratory distress syndrome, and multi organ failure. Such patients may require admission to an intensive care unit (ICU) for critical support and mechanical ventilation. (4).

Patients with severe COVID 19 quickly progressed to acute respiratory failure, pulmonary edema and acute respiratory distress syndrome (ARDS) (5). ARDS is the leading cause of mortality in COVID 19 patients (4). This does not occur due to uncontrolled viral replication alone but also because of an uncontrolled immune reaction from the host. In existence of uncontrolled viral replication, the presence of an increased number of damaged epithelial cells and cell debris activate a massive cytokine release also known as cytokine storm (6).

Elevated pro-inflammatory cytokines and inflammatory biomarkers such as interleukin 6, C-reactive protein (CRP), and ferritin have been shown to be higher in patients with severe COVID-19 and predictors of mortality (7, 8).

In one study, the level of interleukin 6 was noted to have increased tenfold in critically ill COVID 19 patients who required mechanical ventilation or vasopressor support in comparison to those with milder disease and interleukin 6 level correlated with the detection of SARS-CoV-2 RNA (9). These findings suggest that anti-cytokine targeted therapies may be of benefit for patients with severe COVID19. Tocilizumab, a monoclonal antibody against interleukin 6 receptor, was previously approved by Food and Drug Administration for the treatment of cytokine release syndrome (10) and may provide clinical benefit for selected COVID-19 patients with high inflammatory biomarkers.

METHODOLOGY

The patients infected with COVID19, who were treated with Tocilizumab from May 1st to 5th July 2020 at Bahria international Hospital Lahore, were recruited in this retrospective study. All patient identities were kept anonymous. The study was approved by the ethical committee of Bahria International Hospital Lahore. The data utilized, including demographics, laboratory results, and clinical outcomes (PF Ratio) of the patients were obtained from medical records, based on diagnosis and treatment of Pneumonia infected by COVID19 that was classified into four types: mildly ill, moderately ill, seriously ill and critically ill. The serum levels of CRP, D-Dimers and serum Ferritin level observed before and after Tocilizumab administration. CRP, an acute phase reactant reflecting the inflammatory activity, was defined as elevated when it was higher than 5.0 mg/L. The most recent CRP, D-Dimers and serum Ferritin level Tocilizumab administration was selected as the value of before Tocilizumab therapy and the changes of the value after Tocilizumab administration was observed for 10 days. The clinical outcome of the patients was evaluated within 10 days after Tocilizumab therapy. Statistical analysis was done with SPSS, version 21.0. Data were presented as median (min max) or as the number and percentage, as appropriate. The Wilcoxon signed rank test used to compare parameters whenever appropriate. A P value of less than .05 was considered statistically significant.

RESULTS

Sixty patients (47 males and 13 females) with COVID \Box 19 were included in this study. The characteristics of patients, the use of Tocilizumab and other anti \Box inflammatory drugs are summarized in results. The mean age (min \Box max) of the patients was 53.83 (14 \Box 81) years. From a total of 60, 4(6.6%) patients were mildly ill, 9 (14.8%) patients were moderately ill, 27 (44.3%) patients were seriously ill, and 20 (32.8%) patients were critically ill.

All (100%) patients received Tocilizumab, the dose of Tocilizumab used in patients was ranged from 400 to 800 mg (4-8 mg/kg). The laboratory findings of the 60 patients before, and in the first few days summarized below.

The principal concern of this study was to see the effect of Tocilizumab with regards to improving the PF Ratio and CRP reduction in Covid-19 infected patients as mentioned in results PF ratio improved in COVID-19 patients after administration of Tocilizumab the median of PF Ratio before treatment was 108 ($52\Box 362$) and improved up to 128 ($37\Box 406$) after Tocilizumab therapy.

Laboratory perimeters included in this study were CRP. Serum Ferritin, D-Dimers and LDH, values of these parameters before administration of Tocilizumab were highly raised. Mean CRP (min \square max) before administration of Tocilizumab was 110 (8 \square 239) mg/L. D-Dimers before Tocilizumab were 567 (141 \square 1620), whilst Serum Ferritin was 105 (831 \square 1678) and similarly serum LDH was also elevated 128 (447 \square 1485) according to the given results above CRP levels were far above the normal range in all patients before the start of Tocilizumab therapy and were rapidly ameliorated after the Tocilizumab treatment.

After administration of Tocilizumab the lab parameters were changed as CRP decreased down to 0.40 (9.6-73) mg/L but other parameters did not decrease as significantly. D-Dimers after Tocilizumab therapy was 149 ($529 \square 1600$), serum Ferritin 183 ($823 \square 1637$) and LHD increased to 186 ($486 \square 2717$). Importantly the effect of Tocilizumab on CRP was remarkable as it decreased from 110 ($8 \square 239$) mg/L to .40 ($9.6 \square 73$) mg/L (P<.05), in this regard other parameters were constant or changed minimally. Although Tocilizumab has benefits in relieving inflammatory activity, for critically ill patients who received only a single dose of Tocilizumab therapy, prognosis was still unfavorable and the CRP level in the other 5 patients failed to return to normal range during the 10 days long session. In the other patients, CRP levels were in or near the normal range within 10 days. To measure the median difference of lab values and effectiveness of Tocilizumab on those parameters Wilcoxon's Rank test used.

Wilcoxon's ranks			Mean Rank
CRP After Tocilizumab Therapy - CRP Before Tocilizumab Therapy	Negative Ranks	60 ^a	30.50
	Positive Ranks	0^{b}	.00
	Ties	0^{c}	
	Total	60	
Post PF Ratio After Tocilizumab –Pre PF Ratio Before Tocilizumab	Negative Ranks	13 ^m	30.31
	Positive Ranks	47 ⁿ	30.55
	Ties	0^{o}	
	Total	60	
D-Dimers After Tocilizumab Before Tocilizumab Therapy	Negative Ranks	23 ^d	30.15
^ *	Positive Ranks	32 ^e	26.45
	Ties	5 ^f	
	Total	60	
Ferritin After Tocilizumab Before Tocilizumab Therapy	Negative Ranks	26 ^g	27.52
	Positive Ranks	29 ^h	28.43
	Ties	5 ⁱ	
	Total	60	
LDH After Tocilizumab Therapy - LDH After Tocilizumab Therapy	Negative Ranks	20 ^j	29.50
	Positive Ranks	36 ^k	27.94
	Ties	4^1	
	Total	60	

The following table elaborates on the Wilcoxon's rank test description according to this table the 1st pair describe the median CRP before and after Tocilizumab therapy in this case three ranks were seen. In these results all 60 were negative ranks, exhibiting that the median of CRP in all patients decreased significantly in posttest.

The 2nd row describes the effect associated with Tocilizumab therapy in improvement of P/F Ratio according to given results there are 47 Positive Ranks and 13 negative Ranks showing that in maximum cases P/F ratio was Low before Tocilizumab administration and improved after Tocilizumab therapy, only 13 cases did not improve after Tocilizumab administration.

The 3rd pair reports the D-Dimers median before and after, there were 23 negative ranks, 32 positive ranks and 5 ties mean pre and post equal. According to the given values of D-dimers only 23 ranks shows the decrease in post-test 32 positive ranks showed the increase in post-test so D-Dimers values have not decreased as significantly as CRP, after Tocilizumab therapy.

In the case of Ferritin and LDH the results were almost identical to D-Dimers. In the Ferritin row only 25 were negative ranks, 29 were positive and there were 5 ties which described that Ferritin also remained same or higher. According to last row the median LDH was very similar to Ferritin because there were 20 negative 36 positive and 4 ties which elaborated that the majority of patients LDH was high in post-test and some cases presented same value of LDH in pre and post test results.

Test Statistics							
	CRP after	D-dimers after	Ferritin after	LDH after	Post PF Ratio		
	Tocilizumab	Tocilizumab	Tocilizumab	Tocilizumab	after		
	therapy - CRP	therapy - D-dimers	therapy -	therapy - LDH	Tocilizumab		
	before	before	Ferritin before	after	- Pre PF ratio		
	Tocilizumab	Tocilizumab	Tocilizumab	Tocilizumab	before		
	therapy	therapy	therapy	therapy	Tocilizumab		
Ζ	-6.736 ^b	641 ^c	663 ^c	-1.697 ^c	-3.835 ^d		
Asymp. Sig. (2-	.000	.522	.507	.090	.000		
tailed)							
a. Wilcoxon Signed Ranks Test, b. Based on positive ranks, c. Based on negative ranks, d. Based on negative ranks.							

Table No: 2 describes the test statistics of lab values, P/F Ratio and effects of Tocilizumab on these variables in pair of CRP and P/F Ratio before and after the P-value was .000 that was less than 0.05 that showed the beneficial effect associated with use of Tocilizumab in decreasing of CRP and improving of P/F Ratio to a remarkable level. In D-Dimers case significant value of D-dimers before and after was .522 that was greater than .05 similarly in the 3^{rd} and 4^{th} pair significant value is greater than P-value so other lab values were not decreased in response to Tocilizumab

DISCUSSION

A study described the clinical characteristics and outcomes of 25 patients who received Tocilizumab therapy for severe COVID \Box 19. Unsurprisingly, all patients were in ICU at the time of Tocilizumab initiation(11).

In our study sixty patients (78%) 47 males and (21%) 13 females with COVID19 were included. The characteristics of patients, the use of Tocilizumab and other anti-inflammatory drugs are summarized in results. The mean age (min-max) of the patients was 53.83 (14 \square 81) years.

All (100%) patients received Tocilizumab. The dose of Tocilizumab used in patients was in the range from 400 to 800 mg. The laboratory findings of the 60 patients before, and in the first few days.

Improved P/F ratio in COVID19 patients was associated with administration of Tocilizumab the median of P/F Ratio before treatment was 108 ($52 \Box 362$) and improved up to 128 ($37 \Box 406$) after Tocilizumab therapy.

Another study narrated that at admission, 25 patients had fever, which resolved in 24 patients within 24 hours of the treatment. Furthermore, PaO_2/FiO_2 improved during the follow-up period (baseline, 152 ± 53 ; day 7, 283.73 ± 115.9 ; day 14, 302.2 ± 126 ; P < .05). Also, the CRP, ferritin, and D-dimer levels and lymphocyte count improved (12).

In our study we tried to evaluate the beneficial effects associated with use of Tocilizumab in treatment of Covid19 patients. Our findings indicated that Tocilizumab appeared to be associated with beneficial effects in decreasing the inflammatory markers significantly. In most patients, acute phase reactant levels were also decreased and the patients were achieving a relatively stable condition reflected by a decrease in CRP value after Tocilizumab administration. In this study the CRP was 110 (8-239) mg/L before Tocilizumab administration and decreased to 0.40 (9.6-73) mg/L after Tocilizumab therapy.

Similar results were shown in a study conducted in March 2020 described the effectiveness of Tocilizumab in treatment of Covid-19 Tocilizumab proved to be a significant factor in the improvement of oxygenation and decreasing CRP back to physiological levels and a later gradual decrease of IL \square 6 may benefit from the inhibition of inflammatory activity by Tocilizumab resulting in stabilization or improvement of clinical outcome(13).

Moreno-Pérez O described the CRP levels were far above the normal range in all patients before the start of Tocilizumab therapy, and were rapidly ameliorated after the Tocilizumab treatment. The value of CRP Post-Tocilizumab therapy was significantly decreased compared with Pre-Tocilizumab therapy, which dropped from 126.9 ($10.7 \Box 257.9$) to 11.2 ($0.02 \Box 113.7$) mg/L (P < .01). (14)

CONCLUSION

In summary, Tocilizumab was associated with improvement in P/F Ratio and CRP significantly in COVID19 patients but there was not a noteworthy change with regards to other markers after administration of Tocilizumab in severely ill COVID19 patients. Tocilizumab seems to be an effective adjunct in treatment of severely sick COVID19 patients, which could provide a possible therapeutic strategy for this fatal disease, furthermore our result should be evaluated with caution despite the fact that we reported a good response in patients with Tocilizumab. The sample size was small and using laboratory parameters to define disease activity is challenging.

REFERENCES

1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19: towards controlling of a pandemic. The Lancet. 2020;395(10229):1015-8.

2. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20.

3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42.

4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.

5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine. 2020;8(4):420-2.

6. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Nature Publishing Group; 2020.

7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine. 2020;46(5):846-8.

8. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases. 2020.

9. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clinical Infectious Diseases. 2020.

10. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell□induced severe or life□threatening cytokine release syndrome. The oncologist. 2018;23(8):943.

11. Melody M, Nelson J, Hastings J, Propst J, Smerina M, Mendez J, et al. Case report: use of lenzilumab and Tocilizumab for the treatment of coronavirus disease 2019. Immunotherapy. 2020(0).

12. Khiali S, Khani E, Entezari□Maleki T. A Comprehensive Review of Tocilizumab in COVID□19 Acute Respiratory Distress Syndrome. The Journal of Clinical Pharmacology. 2020;60(9):1131-46.

13. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID 19: A single center experience. Journal of medical virology. 2020;92(7):814-8.

14. Moreno-Pérez O, Andres M, Leon-Ramirez J-M, Sánchez-Payá J, Rodríguez JC, Sánchez R, et al. Experience with Tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. Journal of autoimmunity. 2020:102523.